|
Cancer Cell Research |
Article:
Prognostic value of combination fibrinogen, platelet, neutrophil to
lymphocyte ratio and platelet to lymphocyte ratio in advanced lung
adenocarcinoma
by Leirong Wang, Xiaorui Chi, Lingxin Feng, Zhuang Yu
Cancer Cell Research 2019
6(23) 650-658; published online 28 September 2019
Abstract: A combination of fibrinogen (FBG), platelet (PLT),
neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte
ratio (PLR) (abbreviated as CO-NPF) has been recently evaluated as a
marker for prognostication in lung cancer. While previous study on
CO-NPF has evaluated in lung adenosquamous patients, the combination
of these four markers has not been evaluated in advanced lung
adenocarcinoma yet. In this study, we investigated the significance
of CO-NPF in predicting the survival of patients with advanced lung
adenocarcinoma. 225 patients with pathologically diagnosed lung
adenocarcinoma were enrolled. The cutoff values for FBG, PLT, NLR
and PLR were defined by receiver operating characteristic (ROC). The
CO-NPF was calculated as the combination of FBG, PLT, NLR and PLR
based on these cutoff values. Kaplan-Meier analysis and Cox
proportional hazard models were used to assess the prognostic value
of CO-NPF. Kaplan-Meier analysis reveals that CO-NFP was associated
with poorer progressive free survival (PFS) [hazard ratio (HR),
0.657; 95% confidence interval (CI), 0.501-0.862; P=0.002] and
overall survival (OS) (HR, 0.701; 95% CI, 0.523-0.938; P=0.016). Cox
proportional hazard models further reveals CO-NFP as an independent
prognostic factor for PFS (HR, 0.665; 95% CI, 0.504-0.876; P=0.004)
and OS (HR, 0.672; 95% CI, 0.495-0.914; P=0.011). CO-NPF can serve
as a useful biomarker to predict recurrence and death for patients
with advanced lung adenocarcinoma.
Open Access Download
(free) PDF
|
Article:
The potential use and clinical significance of plasma RIPK3 in
distinguishing malignant from benign lung lesions
by Wei Sun, Wencheng Yu, Yanan Zhang, Shichao Cui
Cancer Cell
Research 2019
6(23) 659-665; published online 28 September 2019
Abstract: To evaluate the potential value of the plasma
level of receptor- interacting protein kinase 3 (RIPK3), a key
protein involved in the activation of necroptosis, as a
biomarker for the differential diagnosis of lung cancer in
patients with lung lesions detected by chest computed
tomography. The subjects of this study were divided into 3
groups: lung cancer (n = 30), benign disease (n = 13), and
healthy controls (n = 33). The measurement of plasma RIPK3 was
performed by enzyme-linked immunosorbent assay. The plasma RIPK3
level in patients with lung cancer (1467.4 ± 347.4 pg/ml) was
significantly higher than that in patients with benign disease
(1219.8 ± 156.4 pg/ml) and healthy controls (746.2 ± 255.3
pg/ml). Besides, plasma RIPK3 levels that were greater than
970.06 pg/ml provided 96.7% sensitivity and 84.8% specificity
for lung cancer. Our results show that plasma RIPK3 levels are
higher in lung cancer patients. We suggest that plasma RIPK3
level could be used as an auxiliary tool for distinguishing lung
cancer from benign lesions and healthy lungs.
Open Access Download
(free) PDF
|
Chronic Diseases
Prevention Review |
Article:
Vivo study of MSCs on EPCs cells in ischemic heart disease
by Jianming Wang, Gengbiao Chen, Youfeng Guo, Xiaohong
Yin, Xiaodong Wang
Chronic Diseases Prevention Review
2019 3(12) 1-5; published online 18 July 2019
Abstract:
The treatment of ischemic heart disease mainly depends on the
formation of blood vessels and the survival of cardiac myocytes.
This paper will research the enhancement of EPC cells by
mesenchymal stem cells in the treatment of ischemic heart
disease. Mouse bone marrow was collected, MSCs cells were
isolated and cultured. Flow cytometry was used to test the
expression of CD34 and CD44. Then MSCs cells and endothelial
progenitor cells co-culture 48 h, and 24 Wistar rats were
randomly divided into EPCs group, EPCs MSCs + group and the
control group. MSCs 2×106, EPCs 2×106,
EPCs 2×106, and PBS buffer were injected into five
different regions around ischemic myocardium. The changes in
cardiac function were assessed by echocardiography after 4
weeks. MSCs 2×106, EPCs 2×106, EPCs 2×106,
and PBS buffer were injected into five different regions around
ischemic myocardium. The changes in cardiac function were
assessed by echocardiography after 4 weeks. The rats were
sacrificed, and the expression of VEGF was detected by
immunohistochemistry and immunofluorescence. The surface markers
CD34 and CD44 of MSCs and EPCs were differentially expressed. We
successfully isolated MSCs and EPCs cells. Meanwhile, the
proliferation index Ki67 was highly expressed, suggesting that
MSCs could effectively promote the proliferation activity of
EPCs. Echocardiography showed that after MSCs+EPCs treatment,
the left ventricular ejection fraction, end-diastolic volume and
cardiac volume of the rats were significantly improved, with
statistically significant differences from the control group and
the EPCs group (P<0.05), Meanwhile, the expression of VEGF in
MSCs+EPCs group was also significantly increased (P<0.05).
Mesenchymal stem cells can enhance the therapeutic effect of EPC
cells in ischemic heart disease, which can promote myocardial
angiogenesis, improve ventricular remodeling and cardiac
function.
Open Access Download
(free) PDF
|
Article:
Early Screening and Diagnosis of Autism
Chronic Diseases Prevention Review
2019 3(12) 39-44; published online 28 December 2019
Abstract:
Autism
Spectrum Disorders have for some time been the focus of intense
interest for clinicians and researchers because of the high
prevalence of the disorders among children in the community.
Particular attention has been paid to the early diagnosis of the
disorder and to the intensive therapeutic intervention.
Currently the best prognosis for autism lays in the early
diagnosis and intervention. But diagnosis of autism at an early
age is challenging due to the existing phenotypic and
etiological heterogeneity among ASD individuals. There are many
screening scales for autism, but their specificity and
sensitivity vary to varying degrees. Therefore, an efficient
early diagnosis method is needed. This paper presents a review
of the early detection of ASD.
Open Access Download
(free) PDF
|
|